CUMYL-CBMICA

CUMYL-CBMICA
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name 1-(cyclobutylmethyl)-N-(2-phenylpropan-2-yl)indole-3-carboxamide;
ChemSpider	84400460;
Chemical and physical data
Formula	C23H26N2O
Molar mass	346.474 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(NC(=O)c3cn(CC1CCC1)c2ccccc23)c4ccccc4;
	InChI InChI=1S/C23H26N2O/c1-23(2,18-11-4-3-5-12-18)24-22(26)20-16-25(15-17-9-8-10-17)21-14-7-6-13-19(20)21/h3-7,11-14,16-17H,8-10,15H2,1-2H3,(H,24,26); Key:INXXQNIOWMOYEJ-UHFFFAOYSA-N;

CUMYL-CBMICA (SGT-280) is an indole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug,^[1]^[2] first being identified in Germany in August 2019. Since the structure fell outside the German drug analogue law provisions at the time, an amendment was made to the law to expand the relevant definition, which came into effect in April 2020.^[3] It has been shown to act as a CB₁ receptor agonist with an EC₅₀ of 62.9nM.^[4]

References

^ Halter S, Pulver B, Wilde M, Haschimi B, Westphal F, Riedel J, et al. (October 2020). "Cumyl-CBMICA: A new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chain". Drug Testing and Analysis. 13 (1): 208–216. doi:10.1002/dta.2942. PMID 33037749.
^ Polettini AE, Kutzler J, Sauer C, Bleicher S, Schultis W (September 2020). "LC-QToFMS Presumptive Identification of Synthetic Cannabinoids without Reference Chromatographic Retention/Mass Spectral Information. I. Reversed-Phase Retention Time QSPR Prediction as an Aid to Identification of New/Unknown Compounds". Journal of Analytical Toxicology. 45 (5): 429–439. doi:10.1093/jat/bkaa126. ISSN 0146-4760. PMID 32896861.
^ "Draft Ordinance amending the Annex to the New Psychoactive Substances Act. Notification Number: 2020/173/D". Germany. 30 March 2020.
^ Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (November 2020). "in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[1] Halter S, Pulver B, Wilde M, Haschimi B, Westphal F, Riedel J, et al. (October 2020). "Cumyl-CBMICA: A new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chain". Drug Testing and Analysis. 13 (1): 208–216. doi:10.1002/dta.2942. PMID 33037749.

[2] Polettini AE, Kutzler J, Sauer C, Bleicher S, Schultis W (September 2020). "LC-QToFMS Presumptive Identification of Synthetic Cannabinoids without Reference Chromatographic Retention/Mass Spectral Information. I. Reversed-Phase Retention Time QSPR Prediction as an Aid to Identification of New/Unknown Compounds". Journal of Analytical Toxicology. 45 (5): 429–439. doi:10.1093/jat/bkaa126. ISSN 0146-4760. PMID 32896861.

[3] "Draft Ordinance amending the Annex to the New Psychoactive Substances Act. Notification Number: 2020/173/D". Germany. 30 March 2020.

[4] Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (November 2020). "in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.

[1]

[2]

[3]

[4]

CUMYL-CBMICA

See also

References

Navigation menu

CUMYL-CBMICA

See also

References

Navigation menu

Search